Lanadelumab Injection Included in China's 2022 National Reimbursement Drug List, Marking a Milestone for Hereditary Angioedema Treatment Accessibility

2023Year1Month18Takeda China announced that its product for hereditary angioedema (Hereditary Angioedema, HAE) The innovative drug Lanadelumab Injection, developed by Takeda Pharmaceutical Company Limited, has successfully passed the national medical insurance negotiation and has been included for the first time in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2022Year)》(hereinafter referred to as2022National Medical Insurance Drug Catalogue). This is a follow-up to2021YearHAEAfter the emergency treatment drug icatibant acetate injection was included in the medical insurance, another oneHAEThe inclusion of globally innovative treatments in the medical insurance will greatly improve the accessibility of Lanadelumab Injection in China.HAEPatients benefit from standardized treatment.

HAEIs a rare genetic disease,75%The patient in10-30The first episode occurred during the year. The patient lacksC1Esterase Inhibitor (C1INH) or its dysfunction leads to acute edema occurring unpredictably in multiple parts of the body, such as the limbs, face, genitals, respiratory tract, and gastrointestinal mucosa, severely impacting daily work, study, life, and emotional well-being. The majorityHAEThe patient's episodes cannot be accurately predicted. Among them, when laryngeal edema occurs, it progresses rapidly. If not rescued in time, the average...4.6Hours can lead to patient suffocation and death. According to statistics, in China, there are59% ofHAEThe patient experienced laryngeal edema, with a mortality rate as high as40%, posing a serious threat to the lives of patients. Due to frequent occurrences of acute edema without any warning signs, leading toHAEPatients are unable to work and study normally, especially the fear of laryngeal edema attacks makes them live in constant anxiety and fear.

As the world's first targetedHAEMonoclonal antibody (mAb) Drug, Lanadelumab Injection2018Year received approval from the U.S. Food and Drug Administration （FDA) Approval,2021Officially entered China in the year, filling a gap in ChinaHAEThe long-term absence of targeted treatment highlights the globally advanced standardized prevention and treatment protocols. Lanadelumab injection can specifically inhibit activated plasma kallikrein in patients, reducing the disease burden caused by frequent and unpredictable acute edema attacks. . A key clinical study showed that, compared with the placebo group, every2Once a week300Treatment with milligram doses of Lanadelumab injection reduced the average monthly attack rate.87%。（0.26 vs. 1.97，n=27 vs. n=41), stable phase of treatment (after treatment70-182The proportion of patients without edema episodes reached77%。

“Authoritative diagnosis and treatment guidelines both in China and abroad recommendHAEPatients undergo long-term preventive treatment to reduce the frequency of edema episodes and ensure their return to normal life.”Professor Zhi Yuxiang from the Department of Allergy at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, stated,“After Lanadelumab Injection was included in the medical insurance directory, ChinaHAEPatients are also expected to achieve edema.‘Zero Episodes’The treatment goal, which we are very much looking forward to.”

With the inclusion of Icatibant Acetate Injection and Lanadelumab Injection into the medical insurance, ChinaHAEPatients will officially embark on standardized treatment.“Double Insurance”In the era of integrating prevention with emergency treatment, there is hope to comprehensively reduceHAEThe risk of disease onset allows more patients, especially younger ones, to benefit. Among them are young people whose long lives have just begun and those in their prime who bear the responsibilities of society and family.“Access to Medical Care”、“Medical Coverage”Allowing them to finally step out of the shadow of illness and return to a normal life.

ReferenceData

1， Xu YY, Jiang Y, Zhi YX, Yin J, Wang LL, Wen LP, Gu JQ, Guan K, Zhang HY. Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations. Eur J Dermatol. 2013 Jul-Aug;23(4):500-4. doi: 10.1684/ejd.2013.2105. PMID: 24001409.

2， Xu Y Y ,  Zhi Y X ,  Liu R L , et al. Upper airway edema in 43 patients with hereditary angioedema[J]. Annals of Allergy, Asthma & Immunology, 2014.

3， Liu s. et al. Eur j Dermatol.2019.29(11:14-20.

4， Riedl M A , Maurer M , Bernstein J A , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks[J]. Allergy, 2020.

5， P N Nelson, G M Reynolds, E E Waldron, E Ward, K Giannopoulos, P G Murray. Monoclonal antibodies. J Clin Pathol: Mol Pathol 2000;53:111–117.

6， Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018;320(20):2108–2121. doi:10.1001/jama.2018.16773.